
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is positioning itself for potential success with the upcoming launches of AMP-018 and AMP-004, as well as their continued growth in Baqsimi prescriptions. However, the potential for troublesome headwinds in Baqsimi pricing could impact the company's bottom line. As a result, the lack of near-term catalysts and the modest expected top-line growth have led to a Hold rating for the stock.
Bears say
Amphastar Pharma is facing numerous challenges, including competitive headwinds in their generic and proprietary products, particularly with the expected decline in sales of their injectable glucagon product. The company also faces uncertainty regarding the timing and success of their pipeline products, which could impact their top-line and EBITDA growth. As a result, we believe that the stock is currently fairly valued with limited potential for near-term growth, and therefore have a neutral rating and a lowered price target of $21.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares